Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCM Abcam	$23.99	$23.88	$12.48 ▼ $25.32	$5.50B	0.86	3.08 million shs	3,300 shs
CRSP CRISPR Therapeutics	$37.59 +5.5%	$38.15	$30.04 ▼ $67.88	$3.08B	1.88	1.67 million shs	1.96 million shs
DNLI Denali Therapeutics	$14.80 +3.0%	$14.24	$10.57 ▼ $33.33	$2.09B	1.49	1.09 million shs	1.51 million shs
VIR Vir Biotechnology	$5.30 +4.1%	$6.22	$4.95 ▼ $14.45	$731.74M	1.36	1.35 million shs	2.53 million shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCM Abcam	0.00%	0.00%	0.00%	0.00%	0.00%
CRSP CRISPR Therapeutics	0.00%	-6.88%	-9.36%	-9.62%	-30.39%
DNLI Denali Therapeutics	0.00%	-12.47%	+13.31%	-31.08%	-21.41%
VIR Vir Biotechnology	0.00%	-17.37%	-7.96%	-45.74%	-46.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCM Abcam	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.8641 of 5 stars	4.3	1.0	0.0	0.0	1.7	3.3	0.6
DNLI Denali Therapeutics	3.9223 of 5 stars	4.5	0.0	0.0	4.7	2.0	1.7	0.0
VIR Vir Biotechnology	2.7102 of 5 stars	3.4	1.0	0.0	0.0	2.4	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCM Abcam	0.00	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.75	90.88% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.79	128.28% Upside
VIR Vir Biotechnology	2.86	Moderate Buy	$32.86	519.95% Upside

Current Analyst Ratings Breakdown

Latest CRSP, DNLI, ABCM, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $14.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$53.00 ➝ $47.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $81.00
5/7/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $82.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2025	VIR Vir Biotechnology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $21.00
4/10/2025	DNLI Denali Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight

(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCM Abcam	$379.70M	14.49	$0.60 per share	40.17	$3.92 per share	6.12
CRSP CRISPR Therapeutics	$35M	92.75	N/A	N/A	$22.52 per share	1.67
DNLI Denali Therapeutics	$330.53M	6.50	N/A	N/A	$7.42 per share	1.99
VIR Vir Biotechnology	$14.30M	51.16	N/A	N/A	$11.82 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCM Abcam	-$10.51M	N/A	0.00	42.09	2.19	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/14/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	N/A
VIR Vir Biotechnology	-$615.06M	-$4.22	N/A	N/A	N/A	-678.40%	-36.71%	-31.00%	7/30/2025 (Estimated)

Latest CRSP, DNLI, ABCM, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.26	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
2/27/2025	Q4 2024	DNLI Denali Therapeutics	-$0.75	-$0.67	+$0.08	-$0.67	$12.75 million	N/A
2/26/2025	Q4 2024	VIR Vir Biotechnology	-$0.85	-$0.76	+$0.09	-$0.76	$8.14 million	$12.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCM Abcam	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCM Abcam	N/A	1.35	1.00
CRSP CRISPR Therapeutics	N/A	22.07	22.07
DNLI Denali Therapeutics	N/A	9.98	9.98
VIR Vir Biotechnology	N/A	8.94	8.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCM Abcam	90.45%
CRSP CRISPR Therapeutics	69.20%
DNLI Denali Therapeutics	92.92%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
ABCM Abcam	6.73%
CRSP CRISPR Therapeutics	4.30%
DNLI Denali Therapeutics	7.90%
VIR Vir Biotechnology	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCM Abcam	1,760	229.27 million	213.84 million	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.26 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
VIR Vir Biotechnology	580	138.06 million	116.24 million	Optionable

CRSP, DNLI, ABCM, and VIR Headlines

Recent News About These Companies

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12 at 4:05 PM | businesswire.com

Bridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

May 12 at 4:46 AM | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LP

May 11 at 3:51 AM | marketbeat.com

Vir Biotechnology First Quarter 2025 Earnings: Revenues Disappoint

May 10 at 4:47 PM | finance.yahoo.com

DAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 10 at 7:41 AM | marketbeat.com

Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%

May 10 at 6:34 AM | aaii.com

Q1 2025 Vir Biotechnology Inc Earnings Call

May 10 at 1:34 AM | finance.yahoo.com

Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2

May 10 at 1:34 AM | fiercebiotech.com

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9 at 7:04 AM | businesswire.com

Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress

May 8, 2025 | tipranks.com

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025 | seekingalpha.com

Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus

May 8, 2025 | msn.com

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

May 8, 2025 | uk.finance.yahoo.com

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

May 7, 2025 | zacks.com

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025 | businesswire.com

1,084,539 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Baker BROS. Advisors LP

May 6, 2025 | marketbeat.com

Wells Fargo & Company MN Has $387,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 6, 2025 | marketbeat.com

Barclays PLC Has $1.62 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 5, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Invests $1.48 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 3, 2025 | marketbeat.com

Tower Research Capital LLC TRC Has $451,000 Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRSP, DNLI, ABCM, and VIR Company Descriptions

Abcam NASDAQ:ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

CRISPR Therapeutics NASDAQ:CRSP

$37.59 +1.97 (+5.53%)

Closing price 04:00 PM Eastern

Extended Trading

$37.60 +0.01 (+0.02%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Denali Therapeutics NASDAQ:DNLI

$14.80 +0.43 (+2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$14.94 +0.14 (+0.91%)

As of 06:18 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Vir Biotechnology NASDAQ:VIR

$5.30 +0.21 (+4.13%)

Closing price 04:00 PM Eastern

Extended Trading

$5.28 -0.01 (-0.28%)

As of 07:57 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time